These findings may offer insight into the management and treatment of bone fractures as the osteoanabolic drugs that show therapeutic potential in fracture healing, namely PTH and romosozumab, mediate their stimulatory effects either via GαS signaling to increase Wnts or modulation of sclerostin, both leading to increased canonical Wnt signaling. This evidence concerns the gene PTH and bone fracture.